Extended Data Fig. 8: PDT therapy of NP3 for concurrent inhibition of primary and metastasis tumours in B16F10 tumour-bearing mice model.
a, Therapeutic schedule of the antitumour and anti-metastatic study. b, Primary tumour volume curves of the B16F10 tumour-bearing C57BL/6 mice after treatment with PBS, Ce6, Ctrl-NP3, or NP3 (Ce6-equiv. dose, 2.5 mg/kg) in the presence or absence of light irradiation (660 nm, 200 mW/cm2, 5 min) over 10 days. c, Photographs of B16F10 tumours dissected from the mice at the end of treatments. d, Changes in the body weights of B16F10 tumour-bearing mice during different treatments. e, The mean tumour weight of B16F10 tumours from the mice at the end of treatments. f, Tumour inhibition rate of PBS (+), Ce6 (L-), Ctrl-NP3 (L-), NP3 (L-), Ce6 (L+), Ctrl-NP3 (L+), and NP3(L+) in B16F10 tumour-bearing mice model, respectively. g, Optical images and the H&E staining of lung tissues at the end of treatments. h, The calculated lung metastasis nodes of the C57BL/6 mice at the end of treatments. In b-f,h, n = 4 mice. Data are presented as the mean ± s.d. Statistical significance was calculated via one-way ANOVA with Tukey’s multiple comparisons test (b,e,f,h). In g, the representative H&E images are shown from three mice per group.
